|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
bioMerieux and ExonHit Therapeutics initiated a collaboration to develop a blood test to assist physicians in deciding whether to proceed with surgery for prostate cancer using a DNA biochip. The collaboration is based on the expertise and intellectual property of ExonHit in the analysis of genome expression. bioMerieux also entered into a worldwide exclusive license agreement for rights developed by NorChip to an m-RNA based HPV test, for early detection of cervical cancer. The test will use the NucliSENS EasyQ platform and be available during the second quarter of 2007. BioNanomatrix will work with the National Cancer Institute to develop technology to measure DNA damage caused by ionizing radiation therapy in cancer treatment. BioNanomatrix will use its Nanoanalyzer as the basis of a system for quantifying the extent of DNA damage during treatment. Cepheid and BioMerieux plan to develop and market a line of sepsis tests and assays to identify fungi and bacteria and genetic markers for antibiotic resistance. The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide. As part of the deal, BioMerieux has licensed Cepheid patents for its MRSA test. diaDexus, Inc. formed a collaboration with Mayo Validation Support Services to investigate a test featuring a select panel of tumor-specific genes to aid in patient risk stratification and assist in chemotherapy treatment decisions for breast cancer patients. The test uses gene expression profiling to predict recurrence of malignancy in patients diagnosed with primary invasive early stage breast cancer. Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications. Ikonisys Inc. received FDA clearance to market its oncoFISH bladder diagnostic application used on the company’s Ikoniscope robotic digital microscopy platform. The test enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer .Illumina, Inc. and the Children's Hospital of Eastern Ontario formed a research collaboration to develop molecular diagnostic tests to screen newborn babies for spinal muscular atrophy (SMA) and hemoglobinopathies. The tests will utilize Illumina's VeraCode technology and run on the Company's BeadXpress reader, scheduled for market availability before the close of the first quarter, 2007. Illumina will gain global commercialization rights to assays developed under the collaboration. QIAGEN launched the QIAcube, a compact platform that allows users to fully automate the processing of almost all QIAGEN consumable products that today are used manually in over 40,000 laboratories throughout the world.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@total.net with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: February 04, 2007 |
![[Page Banner Image]](images/hmole.gif){kind=small}
